Continuous Monitoring of Vital Signs at Home (WARD HOME II)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-03

Study Completion Date

2025-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to investigate the use of wireless, continuous monitoring in patients at home including the frequency of alarms triggered by abnormal vital parameters and their significance for (re)hospitalisation/Serious Adverse Events(SAE) and/or death within 30 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

WARD-Home - Continuous Monitoring of Vital Parameters After Discharge

NCT05223504

Vital Sign Clinical Deterioration

COMPLETED

Continuous and Wireless Vital Sign Monitoring in Patients at Home After Acute Medical Admission

NCT05536206

Vital Sign Monitoring Clinical Deterioration Disease Progression +1 more

COMPLETED

Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Participants at Home and During Hospitalization

NCT05378139

Surgical Complication Pulmonary Disease Hematologic Diseases +3 more

RECRUITING

Continuous Monitoring of Vital Parameters for Early Detection of Clinical Deterioration in Hospitalized Patients

NCT04305262

Continuous Wireless Vital Parameter Monitoring

WITHDRAWN

Alert Burden When Monitoring Patients at Home

NCT07096648

Continuous Monitoring Vital Signs Monitoring Hospital at Home +1 more

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute hospital admissions challenge the capacity of the healthcare system. Readmission is common among patients with chronic medical diseases, and many patients admitted for acute conditions are often subsequently observed at the hospital for hours and often with one overnight stay for observation purposes alone. Recent medico technical research has allowed continuous and wireless monitoring of patients' vital signs in-hospital, but the practice at home remains uninvestigated. However, the technology has the potential to relieve hospital overcrowding by offering continuous and real time analytics of vital signs in high-risk patients at home.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vital Sign Monitoring Clinical Deterioration Hospital At Home

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Continuously monitoring

Included patients are monitored with WARD equipment the first days after discharge. Monitoring will last for a maximum of three days.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Adult patients (≥18 years) admitted (with at least one night stay) with an acute medical disease and scheduled for discharge to their own homes

Adult patients (≥18 years) who have contacted the EMS and, after assessment by paramedic personnel, not deemed sick enough for immediate hospital admission.

Exclusion Criteria

Patients placed on palliative treatment.

Acceptable chronically abnormal vital parameters of SpO2\<88%, MAP\<70, RR\>24, or HR\>110.

Allergy to plaster, plastic, or silicone.

A pacemaker or Implantable Cardioverter Defibrillator (ICD) device.

If the patient was deemed not able to open the front door when visited by the investigator.

Inability to give informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No